par Arix Bioscience PLC (isin : GB00BD045071)
Financial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM
Arix Bioscience PLC (ARIX)
Arix Bioscience plc
Financial Results for the Year Ended 31 December 2022, Publication of Annual Report and Notice of Annual General Meeting
LONDON, UK, 25 April 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, today announces its financial results for the full year ended 31 December 2022 (the “Period”) alongside the Annual Report and Accounts together with its Notice of 2023 Annual General Meeting (the “AGM”).
Financial highlights
Corporate, strategic and operational progress
Portfolio highlights
Post-Period end
Outlook
Robert Lyne, CEO of Arix, commented:
“As for many, 2022 proved more challenging than we had hoped at the start of the year. Markets were performing worse in the fourth quarter than in the same period in 2021 when life sciences stocks first began a steep fall. In the ensuing market correction, we are seeing a more conservative environment and a flight to quality, with the market oriented more towards value.
“Despite these uncertain times, the factors driving growth in the pharmaceutical industry remain unchanged: an ageing population, a rising prevalence of chronic conditions, and an increasing per capita spend on healthcare in developed and emerging markets underscore the inherent value that the sector has to offer.
“For investors such as Arix, unlocking this value requires recovery in the biotechnology sector markets and an increase in licensing and M&A activity. We are confident that the fundamentals will play through when the macro challenges are no longer weighing as heavily on the markets.”
Analyst Briefing: 10:00am BST today, Tuesday 25 April 2023 Management will host a virtual briefing for Analysts at 10:00am BST today. Analysts wishing to join should register their interest by contacting Powerscourt on arix@powerscourt-group.com or on +44 (0)20 7290 1050.
Investor Presentation: 4:00pm BST today, Tuesday 25 April 2023 Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 4:00pm BST today.
The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard or at any time during the live presentation via the "Ask a Question" function.
Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/arix-bioscience-plc/register-investor
Investors who already follow Arix on the Investor Meet Company platform will automatically receive an invitation to the event.
Annual General Meeting
The following documents have today been posted or otherwise made available to shareholders by the Company:
3. Annual Report and Accounts 2022
The Form of Proxy is publicly available on the Company's website: https://arixbioscience.com/investor-relations/document-library The Annual Report and Notice of AGM is also publicly available on the Company’s website: https://arixbioscience.com/investor-relations/document-library
Copies of the above documents have been submitted to the UK National Storage Mechanism. The documents will therefore shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism and at the following address:
Arix Bioscience Plc Duke Street House, 50 Duke Street, London, W1K 6JL, United Kingdom
[ENDS]
Enquiries: For more information on Arix, please contact:
Registrar and Receiving Agent: Equiniti Limited +44 (0) 371 384 2030
Company Secretary: Kin Company Secretarial Limited +44 20 8819 6486
Arix Bioscience plc +44 (0) 20 7290 1050
Powerscourt Group Sarah MacLeod, Ibrahim Khalil, Nick Johnson +44 (0)20 7250 1446
About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
INVESTING IN LIFE CHANGING SCIENCE Annual report and accounts 2022 Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies to deliver superior risk-adjusted returns to shareholders. OUR PURPOSE OUR GOAL OUR VALUES AND EXPECTATIONS Integrity Respect Transparency Collaboration Discipline Accountability CONTENTS
STRATEGIC REPORT HIGHLIGHTS Performance snapshot NAV per share Gross Portfolio net revaluation* Business highlights Capital pool Capital raised by portfolio companies in 2022 Operational highlights > Agreement to acquire Twelve Bio by Ensoma in an all share transaction with concurrent financing which was completed in February 2023 > Reverse merger of Disc Medicine onto Nasdaq completed in December 2022, 15 months after first Arix investment > Cost run rate below 2% of Net Asset Value * Year on year net movement includes investments, FX, and impairment. AT A GLANCE Who we are: We collaborate with experienced entrepreneurs and provide the capital, expertise and global networks to help accelerate the science they have developed into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. We are here for two key reasons. To generate superior returns for our investors and to make a tangible difference to patients’ lives. Investment strategy providing resilience through market cycles Diverse portfolio Therapeutic split Development stage split NAV per share Capital Pool Rolling 36 month goals |